Arthur McGivern

Arthur McGivern

Goodwin

Contact
View Bio
RSS

Latest Posts › Class Action

Share:

Caremark Round II: Beware Red Flags in Drug Development

On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims...more

10/9/2019  /  Board of Directors , Caremark claim , Class Action , Clinical Trials , DE Supreme Court , Food and Drug Administration (FDA) , Securities and Exchange Commission (SEC)
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide